TBPH Theravance Biopharma Forecast, Technical & Fundamental Analysis
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives... Show more
TBPH is expected to report earnings to fall 172.00% to 7 cents per share on August 05
Q2'26
Est.
$0.07
Q1'26
Missed
by $0.07
Q4'25
Beat
by $0.15
Q3'25
Beat
by $0.20
Q2'25
Beat
by $0.41
The last earnings report on May 07 showed earnings per share of -10 cents, missing the estimate of -2 cents. With 227.07K shares outstanding, the current market capitalization sits at 840.31M.
A.I. Advisor
published General Information
General Information
a developer of small molecule pharmaceutical products
A.I.dvisor indicates that over the last year, TBPH has been loosely correlated with SPRC. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if TBPH jumps, then SPRC could also see price increases.
TBPH's RSI Oscillator ascending out of oversold territory
The RSI Oscillator for TBPH moved out of oversold territory on June 03, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 20 similar instances when the indicator left oversold territory. In of the 20 cases the stock moved higher. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where TBPH advanced for three days, in of 293 cases, the price rose further within the following month. The odds of a continued upward trend are .
TBPH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The Momentum Indicator moved below the 0 level on May 14, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TBPH as a result. In of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for TBPH turned negative on May 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 57 similar instances when the indicator turned negative. In of the 57 cases the stock turned lower in the days that followed. This puts the odds of success at .
TBPH moved below its 50-day moving average on May 28, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for TBPH crossed bearishly below the 50-day moving average on June 01, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
The 50-day moving average for TBPH moved below the 200-day moving average on May 04, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TBPH declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for TBPH entered a downward trend on June 08, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. TBPH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.892) is normal, around the industry mean (19.523). P/E Ratio (7.309) is within average values for comparable stocks, (35.904). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.680). TBPH has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.039). P/S Ratio (7.704) is also within normal values, averaging (353.959).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TBPH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
